AGC Agreement termination paves way for commercial partner
Filed with ASX · · 2 pages · English
Earlier from Cambium Bio
- CEO Presentation to 2019 Annual General Meeting
- Chairmans Address to Shareholders
- Japanese Biotech Fund takes up all Rights Issue Shortfall
- Regeneus receives A$1.5 million in R&D Tax Incentives
- Appendix 4E
Later from Cambium Bio
- Directors provide $4m loan facility
- Half-Year Results & Business Update
- Regeneus signs MOU with Kyocera Corporation
- Regeneus receives A$1.6M milestone payment from Kyocera
- Regeneus to be granted new key Progenza patent in U.S.
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio